Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
The details of the poster presentations and discussion sessions are as follows:
Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Poster Discussion Session: Head and Neck Cancers
Final Publication Number: 1050PD
Discussion Session Date/Time:Saturday, October 20, 2018 , 3:00 PM - 4:15 PM CEST
Discussion Session Location: Hall B3 -Room 23 , ICM München,Munich Germany
Poster Session Date/Time:Saturday, October 20 ,9:00 AM CEST toMonday, October 22 ,5:00 PM CEST
Poster Session Location: Hall B4 – ICM München,Munich Germany
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
Poster Discussion Session: Melanoma and Other Skin Tumours
Final Publication Number: LBA45
Discussion Session Date/Time:Saturday, October 20, 2018 ,2:45 PM - 4:05 PM CEST
Discussion Session Location: ICM - Room 14b, ICM München,Munich Germany
Poster Session Date/Time:Saturday, October 20 ,2:45 PM CEST toMonday, October 22 ,5:00 PM CEST
Poster Session Location: Hall B4 – ICM München,Munich Germany
Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy
Poster Session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Final Publication Number: 1265P
Poster Session Date/Time:Sunday, October 21 ,12:45 PM - 1:45 PM CEST
Poster Session Location: Hall A3 – Poster Area Networking Hub, ICM München,Munich Germany
About SD-101
SD-101, the Company's lead clinical candidate, is a proprietary, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide.
About
KEYTRUDA is a registered trademark of
Contact: Ryan Spencer Vice President, Corporate Strategy and Communications 510.665.4618 |
Media Contact: Rachel St. Martin W2O 646.894.5757 rstmartin@w2ogroup.com |
Source: Dynavax Technologies Corporation